CAR T-cell therapy at SinoUnited Health in Shanghai treats relapsed and refractory blood cancers — when standard treatments have stopped working. Find your condition below.
More than 100 international patients have been assessed and over 30 treated with CAR T-cell therapy here across the past two years.
CAR T-cell therapies directed at the CD19 target treat these B-cell cancers.
The most common aggressive non-Hodgkin lymphoma, and the highest-volume CAR-T indication.
Learn about DLBCL and CAR-T /conditions/b-allAn aggressive leukemia of the B-lymphocytes, treated with CAR-T when it returns or resists chemotherapy.
Learn about B-ALL and CAR-T /conditions/follicular-lymphomaA slow-growing non-Hodgkin lymphoma that can become hard to treat after multiple relapses.
Learn about FL and CAR-T /conditions/mantle-cell-lymphomaA rarer, often chemotherapy-resistant non-Hodgkin lymphoma.
Learn about MCL and CAR-T /conditions/pmbclAn aggressive large B-cell lymphoma that starts in the chest, most often diagnosed in younger adults.
Learn about PMBCL and CAR-TCAR T-cell therapies directed at the BCMA target treat multiple myeloma.
A separate CAR-T program for advanced gastric cancer, distinct from the blood-cancer conditions above — its own target, its own page.
"Non-Hodgkin lymphoma," or a stage without a subtype. If you're not sure which of these fits, start a free remote assessment and SinoUnited Health's team will tell you whether CAR T-cell therapy may be an option.
China's NMPA has approved eight CAR T-cell therapies for the conditions listed here. Each condition page links to the therapies approved to treat it.
All eight are administered at SinoUnited Health.
A remote assessment by SinoUnited Health's international care team is free, and you'll hear back within 24 hours.